Sudeep Pharma Ltd (SUDEEPPHRM) is currently trading at 1,066.70 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Sudeep Pharma Limited manufactures pharmaceutical excipients, mineral actives, specialty ingredients, nutrition blends, and emerging battery-grade iron phosphate. Its products serve pharmaceutical, food, nutrition, electric-vehicle, and energy-storage applications, supported by manufacturing facilities in India and Ireland, global sales offices, proprietary processing technologies, regulatory certifications, and more than three decades of mineral-chemistry experience. The company delivered its highest-ever quarterly revenue of Rs.196.7 crore in Q2 FY27, up 21% year-on-year, while EBITDA grew 32% to Rs.73.2 crore. EBITDA margin expanded to 37.2%, indicating favorable product mix and operating efficiencies, although PAT growth of 11% was slower because of lower other income, higher depreciation, finance costs, and taxation. Battery materials represent a potentially transformative diversification beyond the company’s established excipients and specialty-ingredient businesses. Sudeep is building a Dahej iron-phosphate plant, targeting 25,000 MTPA initially and 105,000 MTPA through announced phases, while evaluating an additional 100,000 MTPA to participate in the rapidly expanding LFP battery value chain. The Nandesari greenfield facility has received FDA approval and completed internal validation, with customer validation underway and commercial supplies expected in H2 FY27. Its 51,200 MT capacity should strengthen regulated-market access and materially increase Pharma, Food and Nutrition capacity, while being financed through internal accruals. Internationalization is becoming increasingly important: exports represented 65% of Q2 revenue and 72% during H1 FY27. The NSS acquisition adds European manufacturing and customer relationships, while offices in the United States and Europe support global expansion; however, working-capital days have risen to 215, requiring sharper cash-conversion discipline.

Over the past 52 weeks, Sudeep Pharma Ltd has traded between a low of ₹524.95 and a high of ₹1,376.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Sudeep Pharma Ltd has a market capitalization of approximately 12,773.93. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Sudeep Pharma Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 67.72 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 12,773.93 Cr, Sudeep Pharma Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Sudeep Pharma Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Sudeep Pharma Ltd is 67.72. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Sudeep Pharma’s board is scheduled to consider the unaudited Q2 and H1 FY27 results on October 28, 2026. A company announcement also referred to reporting results on October 29, 2026.

Sudeep Pharma makes high-purity mineral ingredients for pharmaceutical, food and nutrition customers, including excipients, calcium-based ingredients and specialty nutrition products.

The earnings call is scheduled for Wednesday, August 5, 2026 at 11:00 AM IST.